|
· Laquinimod - a clinical trial is planned prior to filing an NDA in the US
· TASQ - an investigator-sponsored Phase I clinical trial launched
- enrolment of patients for Phase III trial proceeding according to plan
· ANYARA - Phase III trial continuing according to plan · 57-57 - a clinical trial in systemic sclerosis/scleroderma initiated · ISI - project is proceeding as planned · RhuDex® - a Phase I clinical formulation study launched · Focusing of the operation; notice of termination of employment to 25 staff members · Net sales SEK 234.6 M (11.4) · Operating loss SEK 100.9 M (Loss: 229.0) · Loss after tax SEK 94,5 M (Loss: 221.1) · Loss per share for the period was SEK 1.38 (Loss: 3.38)
For further information, please contact: Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95 Hans Kolam
CFO
Tel +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Thomson Reuters ONE
HUG#1586221
|
